Lexapro vs Zoloft: How I Choose Between Them

Home > Depression > Lexapro vs Zoloft

Escitalopram and sertraline are the two antidepressants I prescribe most often as a first step, and the evidence supports treating them as near-equivalents for depression. In the 2018 Lancet network meta-analysis of 21 antidepressants, pooling 522 randomized trials and 116,477 adults, every drug beat placebo, and both drugs landed in the small group with the fewest dropouts in head-to-head comparisons (Cipriani and colleagues, Lancet, 2018). Escitalopram also ranked among the more effective drugs in direct comparisons (odds ratios 1.19 to 1.96), while the authors rated the certainty of evidence as moderate to very low.

Patients ask which one is "stronger." The efficacy gap between the two, where one exists, is a point or two on a 60-point depression scale. The choice turns on which anxiety disorder travels with the depression, which side effects a person can least afford, whether pregnancy is planned, what else is on the medication list, and how much room the dose leaves to adjust.

Both drugs sit at the top of the antidepressant rankings

The 2018 analysis updated an earlier one from the same group. In 2009, Cipriani and colleagues analyzed 117 trials with 25,928 participants comparing 12 newer antidepressants (Cipriani and colleagues, Lancet, 2009). Mirtazapine, escitalopram, venlafaxine, and sertraline were more efficacious than duloxetine, fluoxetine, fluvoxamine, paroxetine, and reboxetine; against fluoxetine, the odds ratios were 1.32 for escitalopram and 1.25 for sertraline. Escitalopram and sertraline showed the best acceptability of the twelve.

The 2009 authors concluded that sertraline might be the best starting choice for moderate to severe depression once acquisition cost was weighed alongside efficacy and acceptability; both drugs are now generic, so cost no longer separates them. A Cochrane review of 59 trials found a trend favoring sertraline over other antidepressants on efficacy and acceptability, with the caveat that most included studies were of low quality (Cipriani and colleagues, Cochrane Database of Systematic Reviews, 2010).

In the 2018 update, the picture held. Notably, 73% of the 522 trials were rated at moderate risk of bias, which is one reason I treat the rankings as a guide rather than a verdict.

Head-to-head, the efficacy difference is small

The direct comparison most often cited randomized 212 adults with major depression to fixed-dose escitalopram 10 mg or flexibly dosed sertraline 50 to 200 mg (mean 144 mg) for eight weeks (Ventura and colleagues, Current Medical Research and Opinion, 2007). Depression scores fell 19.1 points with escitalopram and 18.4 with sertraline on the Montgomery-Åsberg scale; 75% and 70% of patients responded. Discontinuation for adverse effects was 2% and 4%. None of these differences reached statistical significance, and the trial had no placebo arm.

A pooled analysis of individual patient data from 16 trials (4,549 patients) found escitalopram 1.1 points better than comparator antidepressants on the same scale, with response rates of 63.7% versus 58.3% (Kennedy and colleagues, Current Medical Research and Opinion, 2009). Importantly, the authors reported that escitalopram's edge over other SSRIs was largely explained by its comparisons with citalopram, its own racemic parent, rather than by comparisons with sertraline.

The data are broadly consistent with equivalent antidepressant efficacy. A one-point difference on a 60-point scale is real at the population level and rarely noticeable for one person.

First-step remission is modest with either drug

Whichever SSRI is chosen first, roughly a third of patients reach remission on it. STAR*D, the largest real-world effectiveness study of antidepressant treatment, treated 2,876 outpatients with citalopram (the racemic form of escitalopram) at a mean exit dose of 41.8 mg per day for up to 14 weeks (Trivedi and colleagues, American Journal of Psychiatry, 2006). Remission was 28% on the clinician-rated Hamilton scale and 33% on self-report; response was 47%, and a substantial share of remissions arrived at or after eight weeks.

Accordingly, patience with an adequate dose is warranted before declaring a drug a failure, and a non-response to either drug is common. The next step, whether a switch, an augmentation, or adding CBT, is covered on the treatment-resistant depression and medication versus therapy pages.

The side-effect profiles differ in predictable ways

Both drugs share the SSRI class effects, and the labels differ in degree. The percentages below come from each drug's label; the trial pools differ (Lexapro figures from depression trials, Zoloft figures pooled across six indications), so they are a rough guide rather than a head-to-head comparison.

Gastrointestinal effects. Sertraline is the more GI-active drug. In pooled placebo-controlled trials, nausea occurred in 26% of sertraline patients versus 12% on placebo, and diarrhea or loose stools in 20% versus 10% (Zoloft prescribing information, 2023). For escitalopram in depression trials, nausea was 15% versus 7% and diarrhea 8% versus 5% (Lexapro prescribing information, 2024). The Cochrane review likewise found more diarrhea with sertraline.

Sexual effects. Ejaculation disorder was reported by 9% of men on escitalopram versus under 1% on placebo; ejaculation failure by 8% of men on sertraline versus 1%. A meta-analysis that relied on direct questioning rather than spontaneous report ranked sertraline highest among SSRIs for treatment-emergent sexual dysfunction and escitalopram near the bottom, with rates across antidepressants ranging from 25.8% to 80.3% (Serretti and Chiesa, Journal of Clinical Psychopharmacology, 2009). That analysis included open-label studies, so the ranking is suggestive. I ask about sexual function before starting either drug and at every follow-up.

Activation and sleep. Sertraline's label lists tremor (9% versus 2%), agitation (8% versus 5%), and insomnia (20% versus 13%); escitalopram's lists insomnia at 9% versus 4% and somnolence at 6% versus 2%. Sertraline tends to feel more activating in the first two weeks, unwelcome when anxiety is already high and useful when the depression is mostly fatigue.

Discontinuation. Both labels carry the same warning: stopping abruptly can produce dizziness, irritability, sensory disturbances, insomnia, and anxiety, and gradual reduction is recommended whenever possible. Half-lives are similar, about 26 hours for sertraline and 27 to 32 hours for escitalopram. When a patient needs to come off either drug, prescribers typically step down over weeks and slow further if symptoms appear.

FDA dosing differs, and so does the room to adjust

Escitalopram is the simpler drug to dose. The label's recommended dose for adults with depression is 10 mg once daily, with a maximum of 20 mg. A fixed-dose trial showed that both 10 mg and 20 mg worked and failed to show greater benefit from 20 mg; dropout for adverse effects at 20 mg was 10%, compared with 4% at 10 mg and 3% on placebo. For patients over 65 and those with liver impairment, the recommended dose stays at 10 mg. Most people land on a single tablet with one possible step up.

Sertraline offers a wider range. For depression and OCD in adults the label starts at 50 mg; for panic disorder, PTSD, and social anxiety it starts at 25 mg. The therapeutic range runs from 50 to 200 mg, increased in 25 to 50 mg steps no more often than weekly. That range helps when a partial responder needs more room. Dosing is individual and decided with the prescriber; these label figures are the starting point for that conversation.

Approved indications tilt the choice

The FDA indication lists are the clearest practical difference between the two. Escitalopram is approved for major depressive disorder in adults and adolescents 12 and older, and for generalized anxiety disorder in adults and children 7 and older. Sertraline is approved for major depressive disorder, obsessive-compulsive disorder, panic disorder, PTSD, social anxiety disorder, and premenstrual dysphoric disorder in adults; in children its only approved use is OCD, from age 6.

Accordingly, when depression arrives with panic attacks, trauma symptoms, obsessions and compulsions, or social anxiety, sertraline covers both conditions on-label. When the companion is generalized anxiety, escitalopram does. Both drugs are used off-label across the anxiety spectrum; the label simply tells me which drug has been through the trials for that condition. For adolescents with depression, escitalopram has the approval; for a child with OCD, sertraline does. The adolescent psychiatry page covers that age group.

Pregnancy, drug interactions, and heart rhythm

Pregnancy. Sertraline is the SSRI I most often reach for when a patient is pregnant or planning to conceive, and the reassurance comes from large cohort data. In a Medicaid cohort of 949,504 pregnancies, 6.8% of women took an antidepressant in the first trimester; after full adjustment, the relative risk of any cardiac defect with SSRIs was 1.06 (95% CI 0.93 to 1.22), and the earlier concern about sertraline and ventricular septal defects did not hold up (relative risk 1.04) (Huybrechts and colleagues, New England Journal of Medicine, 2014). Neither label identifies an established increase in major birth defects. Both describe risks of persistent pulmonary hypertension of the newborn and poor neonatal adaptation with late-pregnancy exposure, a less than twofold increase in postpartum hemorrhage, and a higher relapse rate among women who stopped antidepressants during pregnancy. Observational data cannot establish causation in either direction. The postpartum depression page covers the perinatal decision.

Drug interactions. Sertraline inhibits CYP2D6, more so at higher doses, and its label advises reducing the dose of substrates such as atomoxetine, metoprolol, desipramine, propafenone, and flecainide when needed. Escitalopram at 20 mg has a modest CYP2D6 effect; in one study it doubled desipramine exposure. Escitalopram is metabolized by CYP2C19 and CYP3A4, so poor CYP2C19 metabolizers run higher blood levels at a standard dose, which matters for heart rhythm. Both drugs are contraindicated with pimozide and within 14 days of an MAOI.

Heart rhythm. SSRIs as a class prolong the QTc interval modestly. In a meta-analysis of 16 studies and 4,292 patients, SSRIs lengthened QTc by 6.10 milliseconds compared with placebo in a dose-dependent fashion, and citalopram prolonged it more than sertraline, paroxetine, or fluvoxamine (Beach and colleagues, Journal of Clinical Psychiatry, 2014). Escitalopram's thorough QT study in 113 healthy volunteers found a mean increase of 4.5 milliseconds at 10 mg and 10.7 milliseconds at a supratherapeutic 30 mg, with 6.6 milliseconds predicted at 20 mg. Sertraline's label carries a QTc caution based on post-marketing reports and a 54-subject study showing a concentration-dependent relationship. For a patient with a known long QT, a history of arrhythmia, or other QT-prolonging drugs, I check an ECG before either drug and favor the low end of the dose range, and I am more cautious with escitalopram at 20 mg given its shared chemistry with citalopram.

How I choose between them

One question comes up at nearly every medication visit: "If they're both SSRIs, why would switching from one to the other do anything?" The average effect is the same; the individual response often differs, and the side-effect burden shifts in ways the labels predict. In my practice the decision usually runs as follows.

• Depression alone, or with generalized anxiety. I usually start escitalopram at 10 mg: one tablet, one possible step up, fewer GI effects, and the GAD indication.
• Depression with panic, PTSD, OCD, social anxiety, or PMDD. Sertraline, starting at 25 mg when panic or trauma symptoms are prominent, because the indication covers the comorbidity.
• Pregnant or planning pregnancy. Sertraline, for the cohort data above, decided together with the obstetrician.
• Long QT, arrhythmia history, or QT-prolonging drugs. ECG first, and either drug at the low end of its range.
• A medication list heavy with CYP2D6 substrates (atomoxetine, certain beta-blockers, tricyclics, antiarrhythmics). Escitalopram at 10 mg.
• Prior good response in the patient or a first-degree relative. That drug. A documented history of response outweighs small meta-analytic differences.
• Symptom profile. Fatigue-dominant depression leans toward sertraline's activating profile; anxious, sleepless depression leans toward escitalopram.
• Sexual side effects already a concern. Escitalopram, with the caveat that neither drug is free of them.

Before either drug, I screen for a personal or family history of bipolar disorder, mania, or hypomania, as both labels require, because an antidepressant alone may precipitate a mixed or manic episode in someone with bipolar illness. That evaluation is described on the bipolar disorder page.

Whichever I start, the plan is the same: a standardized symptom scale at each visit, a side-effect check that asks specifically about sexual function and GI symptoms, and a decision point at six to eight weeks on an adequate dose. If the first SSRI fails, switching to the other is a reasonable and common step. Both routes are described on the medication management page, and the depression and anxiety hubs cover the broader plan.

Who this practice fits, and when to go elsewhere

This fits adults starting an antidepressant who want the choice reasoned through, adults who have been on one of these drugs for months without clear benefit, and people started on an SSRI in primary care who want a psychiatrist to take over the plan. It also fits adolescents with depression or anxiety, where dosing and monitoring differ from adult care. Second opinions on a stalled regimen are a regular part of the practice.

Some situations belong elsewhere. Pregnant patients should have the psychiatrist and obstetrician in direct contact. Three or more failed adequate antidepressant trials call for a treatment-resistant depression evaluation rather than a fourth SSRI. Active suicidal thoughts with a plan need an emergency department today.

Cost and booking

Initial evaluations run 60 to 90 minutes and include a full diagnostic assessment and a review of prior medication trials with doses and durations. The practice is out-of-network with all insurance plans; you pay directly and receive a superbill to submit for reimbursement. Fees are listed at out-of-network costs, and this guide walks through checking your plan's out-of-network benefits before the first visit.

Bring a list of every medication and supplement you take, with doses, and any prior antidepressant trials and why they stopped. Schedule a consultation or call (646) 893-4309.

Related

Depression · Anxiety · Medication management · Generalized anxiety disorder · Panic disorder · Treatment-resistant depression · Medication vs therapy vs both · Postpartum depression · Emotional blunting on antidepressants · Antidepressant sexual side effects · Antidepressants and weight gain · Depression with ADHD: combining medications · Anxiety medication options · How long antidepressants take to work · SSRIs for teens · Stopping antidepressants · Wellbutrin vs SSRIs

When Depression Becomes an Emergency

Both drugs carry the FDA boxed warning for increased suicidal thoughts and behavior in children, adolescents, and young adults, and the first weeks after starting or changing a dose are the period to watch most closely. Suicidal thoughts without immediate crisis still warrant same-day or next-day psychiatric evaluation.

Frequently Asked Questions

Is Lexapro or Zoloft better for depression?

For most adults they are equivalent. In the one direct trial of 212 patients, escitalopram 10 mg and sertraline 50 to 200 mg produced nearly identical improvement (19.1 versus 18.4 points) and response rates (75% versus 70%), with no statistically significant difference. Network meta-analyses place both among the best-tolerated antidepressants. The choice usually rests on comorbid anxiety, side effects, pregnancy plans, and drug interactions.

Which is better for anxiety, Lexapro or Zoloft?

It depends on which anxiety disorder. Escitalopram is FDA-approved for generalized anxiety disorder; sertraline is approved for panic disorder, PTSD, social anxiety disorder, and OCD. Both are used off-label across the anxiety spectrum. When depression comes with constant worry, I lean toward escitalopram; when it comes with panic attacks, trauma symptoms, or obsessions, I lean toward sertraline, usually starting at the lower 25 mg dose.

Which has fewer side effects?

Escitalopram, modestly, on gastrointestinal and sexual measures. In label data, nausea affected 26% of sertraline patients versus 15% of escitalopram patients, and diarrhea 20% versus 8%, though the trial pools differ. A meta-analysis using direct questioning ranked sertraline highest among SSRIs for sexual dysfunction and escitalopram near the lowest. Sertraline is also more activating early on. Both carry the same discontinuation and boxed-warning language.

What are the usual doses of Lexapro and Zoloft?

Per the FDA labels, escitalopram for adult depression is 10 mg once daily with a maximum of 20 mg; the fixed-dose trial did not show extra benefit at 20 mg. Sertraline starts at 50 mg for depression and OCD, or 25 mg for panic disorder, PTSD, and social anxiety, with a range of 50 to 200 mg adjusted in 25 to 50 mg steps no more than weekly. Dosing is individual and set with your prescriber.

Which is safer in pregnancy?

Sertraline is the SSRI I most often use when a patient is pregnant or planning to be. In a cohort of 949,504 pregnancies, first-trimester SSRI exposure carried a fully adjusted relative risk of cardiac defects of 1.06, and the specific sertraline concern about septal defects did not hold up. Both labels describe neonatal risks with late-pregnancy exposure, alongside the risk of relapse when antidepressants are stopped.

Can I switch from Zoloft to Lexapro, or the other way around?

Yes, and it is a common step when the first SSRI gives a partial response or troublesome side effects. Because both drugs act on serotonin reuptake and have similar half-lives, prescribers typically either switch directly at comparable doses or briefly overlap the two while one is reduced. The plan is set with your prescriber, who watches for discontinuation symptoms and serotonin syndrome during the transition.

Sources

1. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. PMID 29477251
2. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–758. PMID 19185342
3. Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2010;(4):CD006117. PMID 20393946
4. Ventura D, Armstrong EP, Skrepnek GH, Haim Erder M. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin. 2007;23(2):245–250. PMID 17288677
5. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin. 2009;25(1):161–175. PMID 19210149
6. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. PMID 16390886
7. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259–266. PMID 19440080
8. Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014;75(5):e441–e449. PMID 24922496
9. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397–2407. PMID 24941178
10. U.S. Food and Drug Administration. Lexapro (escitalopram) prescribing information. Revised April 2024. accessdata.fda.gov
11. U.S. Food and Drug Administration. Zoloft (sertraline hydrochloride) prescribing information. Revised August 2023. accessdata.fda.gov